Sacubitril/valsartan was associated with a 13% lower rate of the primary end point, total (first and recurrent) HFH and cardiovascular death, which did not reach statistical significance compared with valsartan alone (rate ratio [RR], 0.87 [95% CI, 0.75–1.01]; P =0.06).
← all excerpts
Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Proteomic Substudy.
2
0.0600
0.0600
The sentences
Despite this potential, we observe only small improvements in discrimination with multiprotein risk scores that are marginally statistically significant and would be unlikely to meaningfully impact clinical care.